Introduction {#Sec1}
============

With the widespread access and use of brain imaging, incidental asymptomatic meningiomas are fast becoming a modern medical issue for neurosurgeons and neuro-oncologists and patients are becoming the so-called Victims Of Modern Imaging Technology (VOMIT) \[[@CR1], [@CR2]\]. Their management consists of surgery, radiosurgery, fractionated radiotherapy and active monitoring. Recent consensus guidelines suggest active monitoring to be the most appropriate management strategy in the first instance; however, the frequency and duration of follow-up are not specified \[[@CR3]\]. This leads to a variety of different monitoring strategies which has economic implications and is of uncertain patient benefit \[[@CR4]\].

Objective {#Sec2}
=========

To evaluate the outcomes of current management strategies of incidental intracranial meningiomas with particular emphasis on active monitoring and the timing of meningioma progression during follow-up.

Methods {#Sec3}
=======

This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement \[[@CR5]\], and has been registered with PROSPERO (CRD42017077928).

Search strategy {#Sec4}
---------------

A literature search, last updated 24/09/2017, was performed in Medline (Ovid), Embase (Ovid), the Cochrane Central Register of Controlled Trials, CINAHL Plus (EBSCO), the WHO International Clinical Trials Registry Platform and UK Clinical Trials Gateway. The search strategy utilized for Medline can be found in Online Resource 1. The strategy adopted for the other databases was altered appropriately and the term "meningioma" was used to search the study registries. The bibliographies of accepted records were examined for additional articles not identified in the initial search.

Paper selection {#Sec5}
---------------

The titles and abstracts of all results were screened independently by two authors (A.I.I. and M.M.) using the population, intervention, comparison, outcome and study design (PICOS) criteria outlined in Table [1](#Tab1){ref-type="table"}. Where disagreements occurred, the senior author (M.D.J.) was consulted to adjudicate.

Table 1PICOS inclusion criteriaPopulationPatients ≥ 16 years of age diagnosed radiologically with an incidental asymptomatic intracranial meningioma/s. Neurofibromatosis type II associated and radiation-induced meningiomas were excludedInterventionActive monitoring, surgery, SRS, *f*RT, or hospital discharge after the first inpatient/outpatient appointmentComparatorNot requiredOutcomesPrimarySecondaryActive monitoringSurgerySRS*f*RTHospital dischargeAll treatment optionsProgression and time to progression (clinical and radiological)Treatment-related morbidityTreatment-related morbidityTreatment-related morbidityMeningioma-related readmissionsNeurocognitive functionIntervention and time to interventionMeningioma gradeRecurrenceRecurrenceQuality of lifeRecurrenceStudy designRandomized controlled trials and retrospective and prospective case series and cohort studies with ≥ 10 adult patients. Case reports were excluded*SRS* stereotactic radiosurgery, *f*RT fractionated radiotherapy

Relevant registered trials were categorized, based on recruitment status, into concluded or on-going. If concluded, disseminated results were examined. If yet to be disseminated, investigators were contacted for data involving incidental meningioma patients. On-going trials were excluded.

Data extraction {#Sec6}
---------------

A standardized pre-piloted proforma (Online Resource 2) was used to extract data from included studies. In the event that a study's population was comprised in part of incidental meningioma patients, the corresponding author was contacted via email to request the raw study data. Data sets that subsequently remained incomplete were handled using the following imputation approach:

i.Studies in which incidental meningioma patients comprised ≥ 90% of the cohort, weighted averages were quoted and used for quantitative analysisii.Studies with a lower percentage were excluded

Data were inputted into Microsoft Excel v16.0 before being exported to statistical software for analysis.

Data synthesis {#Sec7}
--------------

Meningioma location was categorized into non-skull base and skull-base. Further subdivision according to the International Consortium on Meningioma classification system (Online Resource 3) was carried out where appropriate. Meningioma size was recorded as reported in each study. Volumetric measurements were converted to diametric measurements using the equation $\documentclass[12pt]{minimal}
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                \begin{document}$${\text{mean}}~{\text{tumor}}~{\text{diameter}} = \sqrt[3]{{2~ \times {\text{volume}}}}$$\end{document}$ and vice versa \[[@CR6]\]. Diametric measurements were used for prognostication whereas changes in tumor size over time were performed using volumetry. Post-intervention morbidity and presenting symptoms were grouped into hierarchical domains where necessary. Extent of resection for patients who underwent surgery was categorized into gross total resection (GTR) (Simpson grades I--III) and subtotal resection (STR) (Simpson grades IV--V).

Statistical analysis {#Sec8}
--------------------

Study-level data were collated and presented as number (percent), mean (standard deviation \[SD\]) or median (interquartile range \[IQR\]), based on the type of data. The pooled rates (95% confidence interval \[95% CI\]) of primary outcome measures were determined using the proportion meta-analysis function in StatsDirect v3.0, where proportions were transformed using the Freeman--Tukey double arcsine method \[[@CR7]\], before an inverse-variance weighted random effects meta-analysis was performed. Heterogeneity across studies was estimated using the I^2^ statistic and classified into low (≤ 25%), moderate (\~ 50%) and high (≥ 75%). Analysis of prognostic factors comprised three parts; firstly, the relationship between baseline covariates and outcomes were assessed on a non-weighted univariate level. Secondly, weighted meta-analyses were performed using risk difference (RD) as an effect size. Thirdly, the prognostic impact was assessed on a multivariate level using individual patient data (IPD).

### Simple pooled analysis {#Sec9}

Statistical differences for categorical variables were assessed using the Chi square test. Continuous variables were examined using the Mann--Whitney U test or Student's *t* test. Differences were considered to be statistically significant at p \< 0.05. These analyses were performed in an attempt to maintain data for single-arm prognostic or outcome cohorts with no relevant comparators. Data were analysed using SPSS v24.0.

### Meta-analysis {#Sec10}

The effect size measured was RD (95% CI) with forest plots used for graphical representation. If a 95% confidence interval included zero, analysis was deemed statistically non-significant. The Mantel--Haenszel model was used to combine the results from the studies included with weighting per study performed using random effects. Heterogeneity was measured and categorized as described above. All analyses were performed using RevMan v5.3.5.

### Multivariable regression analysis {#Sec11}

Pooling of IPD pertaining to ≥ 2 tested baseline variables was carried out wherever possible and statistical significance was assessed using a backward stepwise binary logistic regression analysis. Significance was set at p \< 0.05. To account for heterogeneity across studies, a multi-level model was utilized with random effects at the level of studies. Odds ratios (OR) with 95% CI were calculated to determine effect size. Analyses were performed in Stata v14.1.

Quality and bias assessment {#Sec12}
---------------------------

Each study was assessed using the NIH Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies \[[@CR8]\], by two authors (A.I.I. and M.M.). This tool addresses internal validity criteria such as selection, measurement, and outcome biases. Results were compared and in case of discrepancies, the senior author (M.D.J.) was consulted. The strength of evidence for each primary outcome was subsequently examined using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) framework which consists of the following domains: (i) risk of bias, (ii) heterogeneity, (iii) directness, (iv) precision and (v) reporting bias. Heterogeneity was assessed using the I^2^ statistic, as described previously. Directness was evaluated using the PICO format. Examination of 95% CIs provided the primary approach to decisions regarding precision. For each treatment group, study-level reporting bias was assessed using Harbord's and Begg's tests and visualized for asymmetry using a funnel plot \[[@CR9], [@CR10]\]. Sensitivity analysis, using a trim-and-fill method \[[@CR11]\], was utilized to recalculate pooled effect size if reporting bias was detected.

Results {#Sec13}
=======

Literature search and study characteristics {#Sec14}
-------------------------------------------

Figure [1](#Fig1){ref-type="fig"} describes the study selection process. The initial number of studies included was 20. The corresponding authors for an additional 11 records were contacted. A duration of 3 months was allowed for responses and follow-up emails were sent to those expressing interest in providing data; however, no responses were received and therefore the final number of studies remained 20. The characteristics of these studies are summarized in Online Resource 4.

Fig. 1PRISMA flowchart demonstrating the study selection process

Baseline characteristics {#Sec15}
------------------------

The overall number of incidental meningioma patients was 2130. Eighteen studies comprising 2061 (96.8%) patients were examined for quantitative analysis \[[@CR12]--[@CR29]\] and two studies (69 patients) were used for a narrative review of quality of life (QoL) and neurocognitive function (NCF) outcomes \[[@CR30], [@CR31]\]. The commonest indications for brain imaging amongst patients with available data (n = 745) were neurological deficit (14.4%), headache (13.6%), audiovestibular symptoms (11.8%) and head injury (10.3%). These were all deemed unrelated to the meningiomas discovered. Baseline characteristics are outlined in Table [2](#Tab2){ref-type="table"}.

Table 2Baseline clinical and radiological characteristicsNo. of studies informing characteristicNo. of valid cases informing characteristic (%)CharacteristicsTotalSurgerySRSActive monitoringP182050No. of patients (%)2050560 (27.3)450 (22.0)1040 (50.7)12803 (39.2)Mean age, years (SD)63.1 (6.9)61.5 (4.7)54.9 (NR)^b^64 (6.9)\< 0.001171919 (93.6)Sex, N (%)Female1526294 (19.3)375 (24.6)857 (56.2)\< 0.001Male393164 (41.7)75 (19.1)154 (39.2)161465 (71.5)Location, N (%)^a^Non-skull base1012269 (26.6)233 (23.0)510 (50.4)\< 0.001Convexity48412986269Parafalcine2475571121Parasagittal153403677Tentorial61112822Intraventricular243129Skull base453113 (24.9)153 (33.8)187 (41.3)Anterior midline113304340Sphenoid wing100241162Posterior fossa---lateral and posterior48221214Posterior fossa---midline14318873415888 (43.3)Mean diameter, cm (SD)2.14 (0.61)2.11 (0.42)1.73 (NR)^b^2.19 (0.66)\< 0.00110615 (30.0)Calcification, N (%)No38055 (14.5)NR325 (85.5)0.774Yes23536 (15.3)NR199 (84.7)5298 (14.5)Tumor signal intensity, N (%)Hyperintense12040 (33.3)NR80 (66.6)0.237Iso/hypointense17848 (27.0)NR130 (73.0)121097 (53.5)Peritumoral edema, N (%)Yes23157 (24.7)19 (8.2)155 (67.1)\< 0.001No866135 (15.6)370 (42.7)361 (41.7)*NR* not reported, *SRS* stereotactic radiosurgery^a^One study which dichotomized location into supratentorial and infratentorial was excluded \[[@CR15]\]^b^Available in one study which did not report SD \[[@CR25]\]

Treatment groups and outcomes {#Sec16}
-----------------------------

At initial presentation, three management strategies were identified; surgery (n = 560, 27.3%), stereotactic radiosurgery (SRS) (n = 450, 22.0%) and active monitoring (n = 1040, 50.7%). No patients received fractionated radiotherapy (*f*RT). The differences in characteristics amongst the three groups are summarized in Table [2](#Tab2){ref-type="table"}.

### Active monitoring {#Sec17}

#### Follow-up regimens {#Sec18}

Fifteen studies included patients who were actively monitored, of which only six described their follow-up regimens. A maximum follow-up duration for patients who did not experience radiological or clinical progression was not stated. Study-specific follow-up protocols are described in Table [3](#Tab3){ref-type="table"}.

Table 3Active monitoring protocols and terminology used to define growth during follow-upStudyProtocolGrowth definitionTiming of scan following diagnosisMeasurementDefinitionOlivero et al. (1995) \[[@CR13]\]3 months → 9 months → 1--2 yearlyNRNRGo et al. (1998) \[[@CR14]\]NRDiameter≥ 0.5 cmNiiro et al. (2000) \[[@CR16]\]NRDiameter≥ 0.5 cmYoneoka et al. (2000) \[[@CR17]\]NRVolume\> 1 cm^3^/yearNakamura et al. (2003) \[[@CR18]\]6 months → 1 yearlyNRNRSonoda et al. (2004) \[[@CR19]\]3 months → 6 monthlyNRNRHashiba et al. (2009) \[[@CR22]\]NRVolume\> 15%Jo et al. (2010) \[[@CR23]\]6 months → 1--2 yearlyVolume\> 25%Jadid et al. (2014) \[[@CR26]\]1 yearly for a minimum of 10 yearsDiameter\> 0.2 cmLiu et al. (2015) \[[@CR27]\]3--12 monthlyNRNR*NR* not reported

#### Radiological and clinical progression {#Sec19}

Follow-up times were reported for 683 patients, with a weighted mean of 49.5 months (SD = 29.3). During follow-up, 235/1040 (22.6%) meningiomas grew, according to each study-specific criterion for growth (Table [3](#Tab3){ref-type="table"}). Time to first evidence of radiological progression was reported for 69 (29.4%) patients at a weighted mean of 28.5 months (SD = 7.5). Considering the heterogeneity of growth definitions, relevant meta-analyses were not performed.

For 432 patients, symptom status was not reported. Out of the remaining 608 patients, 66 patients developed symptoms (pooled proportion = 8.1% \[95% CI 2.7--16.1\], I^2^ = 88.6%). These included seizure (n = 8), motor deficit (n = 6), cognitive deficit (n = 3), visual deficit (n = 2) and cranial nerve palsy (n = 2). The nature of symptoms was not stated in the remaining 45. Differences in baseline characteristics amongst patient groups are shown in Online Resource 5. Forest plots can be found in Online Resource 6.

#### Intervention endpoints and timeframe for treatability {#Sec20}

Intervention was recommended or carried out in 220 patients (pooled proportion = 24.8% \[95% CI 7.5--48.0\], I^2^ = 98.1%). Indications for treatment were radiological progression (n = 153), development of symptoms (n = 66) and patient preference (n = 1). Surgery was performed in 179 whilst SRS was the intervention of choice in the remainder (n = 30, 14.2%). Two patients were subject to surgery and adjuvant SRS. Weighted mean time-to-intervention, available for 175 patients, was 24.8 months (SD = 18.2); 94.3% were carried out within 5 years of diagnosis whilst 5.7% received an intervention after 5 years, latest being performed 88 months following diagnosis. Differences in baseline characteristics amongst patient groups are outlined in Online Resource 5. Forest plots can be found in Online Resource 7.

#### Baseline radiological characteristics, growth dynamics and symptom development {#Sec21}

IPD were available for 137 patients, 89 (8.6%) of whom had known symptom status by the end of follow-up; mean duration was 39.7 months (SD = 27.7). 17 developed symptoms while 72 remained asymptomatic. Average follow-up time did not differ between the two groups (41.6 vs. 39.2 months, p = 0.753). Differences in radiological characteristics and growth dynamics are shown in Table [4](#Tab4){ref-type="table"}.

Table 4Growth dynamics and symptom development during active monitoring stratified by baseline characteristicsFactorMean AGR (cm^3^/year)PMean RGR (%/year)PSymptom development, yes/total (%)OR (95% CI)MLR PLocationNon-skull base2.140.94253.80.21312/64 (18.8)0.927Skull base1.7930.55/25 (20.0)Diameter≥ 3.0 cm4.00\< 0.00128.40.86315/27 (56.6)34.90 (5.17--160.40)0.001\< 3.0 cm0.6227.32/62 (3.2)CalcificationNo2.420.49938.00.09310/47 (21.3)0.879Yes1.3560.66/25 (24.0)Tumor signal intensityHyperintense2.040.98853.00.26211/41 (26.8)0.866Iso/hypointense2.0236.14/27 (14.8)Peritumoral edemaYes0.340.30155.40.7275/10 (50.0)8.72 (0.35--14.90)0.027No2.3244.712/63 (19.0)*AGR* annual growth rate, *RGR* relative growth rate, *MLR* multi-level regression

### Surgery {#Sec22}

Overall, 741/2050 (36.1%) patients had surgery; 560 were operated at initial presentation whilst 181 were monitored prior to intervention.

#### Extent of resection {#Sec23}

Extent of resection was reported in 300/741 (40.5%) patients. GTR was achieved in 285 (95.0%) whereas STR was performed in 10 (5.0%).

#### Post-operative morbidity and mortality {#Sec24}

Of 533 (71.9%) patients with available post-operative morbidity data, 88 had complications (pooled proportion = 11.8% \[95% CI 3.7--23.5\], I^2^ = 91.7%), which were neurological in 47 (53.4%), surgical in 28 (31.8%) and medical in 13 (14.8%) patients. Mortality data was not reported.

#### Histopathology and recurrence {#Sec25}

Histology reports were available for 316 patients; 303 had WHO grade I meningioma (pooled proportion = 94.0% \[95% CI 88.2--97.9\], I^2^ = 54.6%), 10 (3.16%) had WHO grade II meningioma whilst in 3 (0.95%) the pathology revealed WHO grade III meningioma. There was no tumor recurrence observed in 105 patients during a weighted mean follow-up time of 20 months (SD = 14.2) (pooled proportion = 0.3% \[95% CI 0.2--2.2\], I^2^ = 0.0%).

### Stereotactic radiosurgery {#Sec26}

SRS was the initial treatment in 450 patients. Thirty patients were subject to active monitoring and subsequently underwent SRS due to clinical or radiological progression.

#### Treatment parameters {#Sec27}

Two studies provided data regarding radiosurgical parameters. In one study, the treated mean tumor volume was 3.0 cm^3^ (range 0.2--10.4), and the median marginal dose was 14.5 Gray (Gy) (range 12--20) \[[@CR23]\]. In the other, the treated median tumor volume was 2.7 cm^3^ (range 0.2--10.5). The median prescription dose was 13 Gy (range 10--18 Gy) with a median prescription isodose line of 50% (range 40--60%). The median tumor coverage was 98% (range 81--100%) and the median values (range) of the homogeneity, conformity and gradient indices were 2.0 (1.7--2.5), 1.5 (1.1--2.2), and 2.8 (2.4--3.7), respectively \[[@CR25]\]. No other treatment parameters were reported.

#### Post-SRS complications {#Sec28}

Of 389 patients with available data, 85 patients had the following complications (pooled proportion = 32.0% \[95% CI 10.6--70.5\], I^2^ = 96.3%): headache (n = 22), epilepsy (n = 11), motor deficit (n = 6), scalp paresthesia (n = 6), alopecia (n = 5), dizziness (n = 5), ocular pain (n = 4) and tinnitus (n = 4). Twenty-two patients suffered from asymptomatic peritumoral edema.

#### Response rates {#Sec29}

Radiological response was available for 389/480 (81.0%) patients. 382 (98.2%) meningiomas remained stable whilst 7 demonstrated progression during a weighted mean follow-up time of 40.9 months (SD = 14.6) (pooled proportion = 1.5% \[95% 0.1--4.3\], I^2^ = 96.3%). Adjuvant SRS was performed in two surgery patients for whom progression was not reported.

Meningioma specific mortality {#Sec30}
-----------------------------

Two patients exhibited significant meningioma growth at 12 and 88 months of diagnosis and were subsequently offered intervention but declined. The first patient consequently suffered large intracerebral hemorrhage and died. The post-mortem revealed an angioblastic meningioma, more recently defined as hemangiopericytoma. Further details surrounding the 2nd patient's death were not available.

QoL and NCF outcomes {#Sec121}
--------------------

One study examined NCF and QoL in 21 patients (mean age 63.4 years) and compared them to a matched healthy population \[[@CR30]\]. Meningioma patients fared worse compared to healthy controls on working memory and motor speed. However, there was no correlation between these findings and baseline characteristics. The investigators used the Short Form (36) health survey (SF-36) to assess QoL. The meningioma cohort had lower scores on 2/8 domains namely vitality and general health. A retrospective study of 48 patients (median age 80 years), utilizing a different battery of NCF measures, found no differences in outcomes compared to a matched population \[[@CR31]\]. However, when stratified by tumor location, patients with infratentorial meningiomas performed worse on memory and verbal fluency tests. Patients in both studies were treatment-naive. No studies examined the effect of surgery or SRS on NCF and QoL in incidental meningioma.

Quality and bias assessment results {#Sec32}
-----------------------------------

Quality assessment results for each individual study are summarized in Online Resource 8. Ten studies were rated "good", eight were "fair" and two were "poor". As per the GRADE framework, the quality of evidence informing each pooled risk was deemed to be very low (n = 6) or low (n = 1) (Table [5](#Tab5){ref-type="table"}). The generated funnel plots were suspicious for potential reporting bias when pooling the estimate proportions of intervention (treatment arm: active monitoring) and WHO grade (treatment arm: surgery), however, Harbord's and Begg's tests (p \> 0.05) did not indicate statistically significant bias (Online Resource 9). Reporting bias for studies informing SRS outcomes could not be performed due to the low number of studies (n = 2).

Table 5Level of evidence informing each primary outcome assessed using the GRADE frameworkManagementOutcomePooled risk (95% CI)^a^No. of studies (no. of patients)Quality assessmentType of evidenceRisk of biasHeterogeneityDirectnessPrecisionReporting biasOverallActive monitoringSymptom development8.1% (2.7--16.1)12 (608)+ 2− 1− 1000⨁**◯◯◯** Very lowIntervention24.8% (7.5--48.0)13 (971)+ 2− 1− 10− 10⨁**◯◯◯** Very lowSurgeryMorbidity11.8% (3.7 23.5)5 (533)+ 2− 1− 1000⨁**◯◯◯** Very lowWHO grade I94.0% (88.2--97.9)9 (316)+ 2− 10− 1^b^00⨁**◯◯◯** Very lowRecurrence0.3% (0.2--2.2)2 (105)+ 2− 1+ 1000⨁⨁**◯◯** LowSRSMorbidity32.0% (10.6--70.5)2 (389)+ 20− 10− 1NA^c^⨁**◯◯◯** Very lowRecurrence1.5% (0.1--4.3)2 (389)+ 20− 100NA^c^⨁**◯◯◯** Very lowThe overall quality score was determined based on the sum of the included domains. Type of evidence was based on design of the included studies (+ 2 or + 4); + 2 equates to observational cohort studies and + 4 to randomized controlled trials. Risk of bias score reflected the selection process, measures and outcomes definitions and general methodological and statistical concerns across studies informing each outcome (range − 2 to 0). Heterogeneity was scored using the corresponding I^2^ statistic; low (≤ 25%) = + 1, moderate (\~ 50%) = 0 and high (≥ 75%) = − 1. Directness was graded using PICO taking into consideration year of publication and the use of surrogate outcomes (range − 2 to 0). Precision was based on width of the 95% CI. Reporting bias was categorised into detected (+ 1) and not detected (− 1) and performed for each treatment arm using the outcome with the greatest number of studies. The overall quality for each outcome was considered high (≥ 4 points), moderate (3 points), low (2 points) or very low (≤ 1 point)*NA* non-assessable, *SRS* stereotactic radiosurgery, *WHO* World Health Organization^a^Obtained by random effects model^b^Regrading of meningiomas according to the 2016 WHO classification system of brain tumours could not be performed^c^Could not be assessed due to the low number of studies

Discussion {#Sec33}
==========

This systematic review was conducted to evaluate the current management strategies for incidental meningiomas. Twenty studies, comprising 2130 patients, were included. At initial presentation, half were actively monitored, 27% underwent surgery and 22% were treated with SRS.

Clinical implications {#Sec34}
---------------------

Active monitoring of incidental meningioma is becoming increasingly common \[[@CR32]\], with recent guidelines advocating its use in asymptomatic patients demonstrating no radiological mass effect \[[@CR3]\]. However, while the guidelines recommend annual monitoring after a 6-month scan, they do not provide advice regarding the length of follow-up. This stems from the marked heterogeneity of active monitoring regimens, compounded by poor reporting of time to meningioma progression. Moreover, while the development of symptoms is a clear indication for treatment, no consensus exists as to what constitutes significant meningioma growth and when it may necessitate intervention. To this end, we analaysed growth dynamics for meningiomas greater or less than 3 cm. No significant difference was present in the relative growth rate; however, meningiomas ≥ 3 cm demonstrated a higher absolute growth rate (AGR) and a greater risk of clinical progression. This may suggest the use of AGR as a more clinically relevant measure of incidental meningioma growth, which has also been suggested to correlate with a higher WHO meningioma grade \[[@CR33]\].

Only a quarter of patients undergoing active monitoring demonstrate radiological or clinical progression requiring intervention. Since most incidental meningiomas are histologically benign and the risk of treatment-related morbidity from surgery or radiosurgery is similar to those reported for symptomatic meningiomas \[[@CR34]--[@CR37]\], a policy of active monitoring seems justified. Meningioma progression and subsequent treatment intervention in the vast majority of cases occurs within 5 years of diagnosis. Given the current lack of consensus on the required duration of monitoring, this suggests that for those patients who do not have radiological and/or clinical progression, imaging surveillance beyond 5-years may be less frequently required or unnecessary depending on individual patient demographics including comorbidity. However, it is important to consider these results within the context of meningioma location. Skull base meningioma constitutes a different clinical and biologic disease entity \[[@CR38], [@CR39]\], and the absence of a significant prognostic effect is most likely due to skull-base tumors comprising a minority of truly asymptomatic meningiomas.

Patients with ≥ 3 cm meningiomas and those with peritumoral edema are at a higher risk of symptom development and should therefore be more frequently monitored within the first 5 years of diagnosis. However, an early scan at 3 months is not necessary to rule out metastatic disease as no tumors were reported to be metastatic lesions radiologically misdiagnosed as a meningioma \[[@CR40]\]. An argument could also be made for early intervention in these cases; however, the optimal timing remains unclear and we envisage a cost-effectiveness analysis comparing early and delayed (on evidence of progression) treatment would help inform this decision.

Comparisons to published systematic reviews {#Sec35}
-------------------------------------------

One review assessed the risk factors for development of new or worsened symptoms during follow-up of untreated meningiomas, concluding that patients with bigger meningiomas are more likely to become symptomatic; a finding which we replicated \[[@CR41]\]. Slow meningioma growth was associated with low T2 signal and non-calcification in previous reviews, which attempted a meta-analysis of the presence or absence of meningioma growth during follow-up \[[@CR42]\]. Our analysis demonstrated that high T2 signal and non-calcification were associated with symptom development and intervention respectively, which may have been due to meningioma growth.

Limitations {#Sec36}
-----------

Studies included were retrospective of poor quality and this was evident in the highly heterogeneous meta-analyses and the overall very low level of evidence contributing to each primary outcome. Those studies also spanned a 27-year time-period during which major advances in neurosurgical technology and management guidelines occurred, introducing confounding variables into our analysis. Duration of follow-up for patients subject to active monitoring was not available in all studies and the weighted duration of \~ 5 years indicates that long-term prognosis of incidental meningioma remains unclear. Morbidity could not be stratified based on intervention time---immediate and delayed, which prevented a detailed analysis of post-treatment outcomes. Moreover, severity could not be graded and thus complications were grouped together preventing appropriate estimation of the risk of serious morbidity. This is important since the pooled morbidity risk following SRS was three times the risk following surgery. This is likely due to inclusion of symptoms such as headache, which are seldom reported as side effects in the surgical meningioma literature. These were however maintained in our results as for asymptomatic patients undergoing treatment, a headache which was not present pre-intervention, and which might affect QoL, could be regarded as unfavourable outcome. Moreover, it was not among our objectives to compare and contrast the morbidity of surgery and SRS with the purpose of determining the best intervention for incidental meningioma, but rather to demonstrate that complications do occur and considering most incidental meningiomas remain stable during follow-up, this would disincentivize intervention at initial diagnosis.

Future research {#Sec37}
---------------

Our analysis shows that there are a wide variety of measurements of meningioma growth. A uniform definition is therefore required for ongoing clinical management and future research. Furthermore, the current heterogeneity in the frequency of radiological surveillance requires a unified strategy in order to better identify radiological progression and reduce the costs to healthcare. All studies in this review were retrospective in nature and single-institution. There is a clear need to define a validated core outcome set for data standardization and its subsequent use in prospective multi-center studies investigating the management and outcomes of incidental meningiomas.

Conclusions {#Sec38}
===========

Incidental, asymptomatic intracranial meningiomas are common with no clear consensus on the optimal management strategy. This review demonstrates a wide variation in current clinical practice. Considering that most incidental meningiomas are WHO grade I and reported treatment-related morbidity, the decision to intervene at initial presentation should not be made lightly. Active monitoring might constitute a better strategy and this study shows that the majority of patients who develop clinical or radiological progression will do so within the first 5 years of diagnosis. Regular monitoring may therefore be less frequently required beyond this time point. However, the data used to reach this conclusion has methodological shortcomings. Large prospective multi-center studies are required to develop management algorithms that minimize unnecessary treatment and optimize patient outcomes and quality of life.
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